向CircAURKA通过增强CTNNB1蛋白降解来预防结直肠癌的进展
Zhenqiang Sun1,2, Pengyuan Dang3,4, Yaxin Guo5
1Department of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. fccsunzq@zzu.edu.cn.
Oncogene
|September 28, 2024
概括
像cirCAURKA这样的循环RNA (circRNAs) 通过稳定CTNNB1蛋白来驱动结直肠癌 (CRC) 的进展,促进瘤生长和转移. 这一发现为CRC治疗提供了新的点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 结肠直肠癌 (CRC) 的进展显著影响患者的治疗结果,需要新的向疗法.
- 循环RNAs (circRNAs) 是瘤生物学的新兴调节者,具有潜在的治疗意义.
- 之前的研究发现circaURKA在CRC中表达很高,这表明它在瘤发生中的作用.
研究的目的:
- 研究 circAURKA 在结直肠癌扩散和转移中的功能作用.
- 阐明 circAURKA 影响 CRC 进展的潜在分子机制.
- 探索circaURKA作为高级CRC的治疗点的潜力.
主要方法:
- 在体外细胞培养 (HCT116,SW480) 和体内小鼠模型 (异种移植,转移).
- 功能测试包括EDU和Transwell测试.
- 使用FISH,RNA下拉,RIP和co-IP进行的分子机制研究.
主要成果:
- CircAURKA在CRC组织和细胞中显著过度表达,主要局部在细胞质中.
- CircAURKA促进CRC细胞的增殖和转移,无论是体外还是体内.
- 通过增强ACLY-CTNNB1相互作用,CircAURKA稳定了CTNNB1蛋白,从而推动了CRC的进展.
- 通过m6A甲基化来调节CircAURKA的稳定性.
结论:
- 通过抑制CTNNB1蛋白质降解,CircAURKA促进结直肠癌的进展.
- 准circaURKA为开发用于CRC的新型治疗药物提供了潜在的战略.
- 了解cirCAURKA的作用,可以了解CRC的病原和治疗策略.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Role Of Notch Signalling In Intestinal Stem Cell Renewal
2.1K
Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.1K
Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K


